BeOne Medicines (BEIGF) Gross Margin (2017 - 2026)

BeOne Medicines (BEIGF) has 10 years of Gross Margin data on file, last reported at 88.95% in Q1 2026.

• Gross Margin for Q1 2026 came in at 88.95%, up 372.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 88.31% (up 350.0% YoY), and the FY2025 annual result was 87.49%, up 308.0% from the prior year.
• Gross Margin eased to 88.95% in Q1 2026 per BEIGF's latest filing, from 90.49% in the prior quarter.
• Over five years, Gross Margin peaked at 90.49% in Q4 2025 and troughed at 78.72% in Q1 2022.
• A 5-year average of 84.17% and a median of 83.87% in 2023 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2022 and 2023: Gross Margin slumped 1588 bps in 2022, then soared 742 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 80.66% in 2022, then grew by 3 bps to 83.32% in 2023, then gained by 3 bps to 85.76% in 2024, then grew by 6 bps to 90.49% in 2025, then fell by 2 bps to 88.95% in 2026.
• Business Quant data shows BEIGF's Gross Margin at 88.95% in Q1 2026, 90.49% in Q4 2025, and 86.09% in Q3 2025.